Vincenzo Accurso1, Marco Santoro2*, Salvatrice Mancuso1, Angelo Davide Contrino1, Paolo Casimiro1, Mariano Sardo1, Simona Raso2, Florinda Di Piazza3, Alessandro Perez3, Marco Bono3, Antonio Russo3 and Sergio Siragusa1.
Hematology Division University Hospital Policlinico "Paolo Giaccone",
Via del Vespro 129, 90127, Palermo, Italy, Via del Vespro 129, 90127,
2 Dept. of Surgical, Oncological and Stomatological Disciplines, University of Palermo, Via del Vespro 129, 90127, Palermo, Italy.
3 Department of Surgical, Oncological and Stomatological Disciplines, Section of Medical Oncology, University of Palermo, Via del Vespro 129, 90127, Palermo, Italy.
| This is an Open Access article distributed
under the terms of the Creative Commons Attribution License
(https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
and bleeding events pose a severe risk for patients with Polycythemia
Vera (PV) and Essential Thrombocythemia (ET). Many factors can
contribute to promoting the thrombotic event due to the interaction
between platelets, leukocytes, and endothelium alterations. Moreover, a
significant role can be played by cardiovascular risk factors (CV.R)
such as cigarette smoking habits, hypertension, diabetes, obesity and
dyslipidemia. In this study, we evaluated the impact that CV.R plays on
thrombotic risk and survival in patients with PV and ET.
|Table 1. Characteristics of patients with ET and PV.|
|Table 2.Cardiovascular risk in 403 ET and PV patients.|
|Figure 1. Survival and CVR factors in PV (A) and ET (B) patients.|